2022年1月(yue)，國家(jia)(jia)發展改革委辦公(gong)廳公(gong)布國家(jia)(jia)企業技(ji)術(shu)中(zhong)心2021年評價結(jie)果，72家(jia)(jia)企業技(ji)術(shu)中(zhong)心評分(fen)(fen)(fen)達90分(fen)(fen)(fen)以上，獲批優秀(xiu)。麗(li)珠集(ji)團以90.3分(fen)(fen)(fen)的好(hao)成(cheng)績順利通過評價。

國(guo)家企業(ye)技(ji)(ji)術中(zhong)心(xin)是(shi)指經國(guo)家發改(gai)(gai)委牽頭認定的(de)(de)技(ji)(ji)術創(chuang)新能(neng)力強、研究開發與創(chuang)新水(shui)平在同(tong)行業(ye)中(zhong)處(chu)于領先地位、擁(yong)有自(zi)主知(zhi)識(shi)產(chan)權核心(xin)技(ji)(ji)術、具有國(guo)際競爭(zheng)力的(de)(de)企業(ye)技(ji)(ji)術中(zhong)心(xin)。其資(zi)質(zhi)由(you)國(guo)家發改(gai)(gai)委、科技(ji)(ji)部、財政部、海關總署、稅(shui)務總局(ju)五部委聯合授予(yu)，其認定審核過(guo)程嚴格，是(shi)目前國(guo)內規格最高、影響力最大的(de)(de)技(ji)(ji)術創(chuang)新平臺之一。

一直以來，麗(li)珠集(ji)團堅(jian)持研(yan)(yan)發(fa)創新，擁有“國家中(zhong)(zhong)(zhong)(zhong)藥(yao)現代化(hua)工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)、長效微球技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)國家地方(fang)聯合(he)工(gong)(gong)程(cheng)(cheng)研(yan)(yan)究中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)”國家級研(yan)(yan)發(fa)平臺(tai)(tai)以及“廣東(dong)省(sheng)數字化(hua)中(zhong)(zhong)(zhong)(zhong)藥(yao)工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究開發(fa)中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)、廣東(dong)省(sheng)麗(li)珠醫藥(yao)重點工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究開發(fa)中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)、廣東(dong)省(sheng)麗(li)珠體外診斷工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究開發(fa)中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)、廣東(dong)省(sheng)頭孢菌素(su)藥(yao)物工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)、廣東(dong)省(sheng)發(fa)酵制(zhi)藥(yao)工(gong)(gong)程(cheng)(cheng)技(ji)(ji)(ji)(ji)術(shu)(shu)(shu)(shu)研(yan)(yan)究開發(fa)中(zhong)(zhong)(zhong)(zhong)心(xin)(xin)等(deng)8個省(sheng)級研(yan)(yan)發(fa)平臺(tai)(tai)。參芪扶正注射(she)液、艾普拉唑先后榮獲廣東(dong)省(sheng)科技(ji)(ji)(ji)(ji)進步(bu)一等(deng)獎(jiang)、國家科技(ji)(ji)(ji)(ji)進步(bu)二(er)等(deng)獎(jiang)。

近年來(lai)，麗珠(zhu)集團在化學藥(yao)(yao)、中藥(yao)(yao)、生物藥(yao)(yao)、原料(liao)藥(yao)(yao)、體外診斷(duan)試劑等(deng)領域不(bu)斷(duan)取得突破，持(chi)續聚焦(jiao)創新藥(yao)(yao)主業及高壁(bi)壘復雜制(zhi)劑，推(tui)出了亮丙瑞林等(deng)重磅產品，推(tui)動公司穩步向前發展。

麗(li)珠(zhu)(zhu)集(ji)(ji)團(tuan)(tuan)自2009年起被認定(ding)為國家企業(ye)技術中(zhong)心(xin)，此(ci)次以優秀通過評價，是對麗(li)珠(zhu)(zhu)集(ji)(ji)團(tuan)(tuan)一(yi)直(zhi)以來堅持研發(fa)創新(xin)的高度肯定(ding)，也是對麗(li)珠(zhu)(zhu)集(ji)(ji)團(tuan)(tuan)近(jin)兩年經營成果的一(yi)次全面考核(he)。麗(li)珠(zhu)(zhu)集(ji)(ji)團(tuan)(tuan)將繼續以研發(fa)創新(xin)驅動(dong)發(fa)展，為健康事業(ye)作出新(xin)的、更(geng)大的貢獻！